The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer

Clinical Cancer Research

Volumn 22, Issue 6, 2016, Pages 1510-1519

  Beltran, Himisha ^a   Jendrisak, Adam ^b   Landers, Mark ^b   Mosquera, Juan Miguel ^a   Kossai, Myriam ^a   Louw, Jessica ^b   Krupa, Rachel ^b   Graf, Ryon P ^b   Schreiber, Nicole A ^c   Nanus, David M ^a   Tagawa, Scott T ^a   Marrinucci, Dena ^b   Dittamore, Ryan ^b   Scher, Howard I ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b New York Presbyterian Weill Cornell Medicine ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; CABAZITAXEL; CABOZANTINIB; CARBOPLATIN; CISPLATIN; CYTOKERATIN; DOCETAXEL; ENZALUTAMIDE; ETOPOSIDE; IPATASERTIB; IPILIMUMAB; LENALIDOMIDE; MONOCLONAL ANTIBODY J591; PLACEBO; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TOPOTECAN; BIOLOGICAL MARKER;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL LABELING; CIRCULATING TUMOR CELL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MULTIVARIATE ANALYSIS; NEUROENDOCRINE PROSTATE CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOM FOREST; TUMOR BIOPSY; VISCERAL METASTASIS; BIOPSY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; METABOLISM; METASTASIS; NEUROENDOCRINE TUMORS; PATHOLOGY; PROSTATIC NEOPLASMS; REPRODUCIBILITY; TUMOR EMBOLISM;

BIOMARKERS; BIOPSY; COHORT STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84962313216     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0137     Document Type: Article

References (30)

1. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw 2014;12:719-26.
2. Tagawa ST. Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. J Clin Oncol 2014;32: 3360-4.
3. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012;30:e386-9.
4. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 2014;20:2846-50.
5. Aparicio A, Tzelepi V. Neuroendocrine (Small-Cell) carcinomas: why they teach us essential lessons about prostate cancer. Oncology (Williston Park) 2014;28:831-8.
6. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 2013;5: 179ra47.
7. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014;20:2553-68.
8. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial andmesenchymal composition. Science 2013;339:580-4.
9. Phillips KG, Kuhn P, McCartyOJ. Physical biology in cancer. 2. The physical biology of circulating tumor cells. Am J Physiol Cell Physiol 2014;306: C80-8.
10. Hsieh HB, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006;21:1893-9.
11. Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, et al. Case study of the morphologic variation of circulating tumor cells. Hum Pathol 2007;38:514-9.
12. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012;9:016003.
13. Werner SL, Graf RP, Landers ML, Valenta DT, Schroeder M, Greene SB, et al. Analytical validation and capabilities of the epic CTC platform: enrichment-free circulating tumour cell detection and characterization. J Circulating Biomarkers 2015;4:1-13.
14. Scher HI, Halabi S, Tannock I, MorrisM, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
15. Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P, et al. Cytomorphology of circulating colorectal tumor cells: a small case series. J Oncol 2010;2010:861341.
16. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014;38:756-67.
17. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013;15:1-10.
18. Breiman L. Random forests. Mach Learn 2001;45:5-32.
19. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013;19:1438-49.
20. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012;22:396-403.
21. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1:487-95.
22. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
23. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol 2014;25: 1650-6.
24. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, et al. Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 2015;47:689.
25. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32:65-71.
26. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-80.
27. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19:3621-30.
28. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011;9:997-1007.
29. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 2010;16:1414-20.
30. Chen J, Ho H, Lichterman J, Lu Y, Zhang Y, Garcia MA, et al. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Cancer 2015;121:3240-51.